Moleculin Biotech, Inc.
MBRX$0.42
$-0.60 (-59.26%)
OpenLoading chart...
IndexN/A
Market Cap0.00B
Enterprise Value-0.00B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-0.03
P/SN/A
P/B0.26
P/C-0.17
EV/EBITDA0.14
EV/SalesN/A
EPS (ttm)-15.37
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume18.16M
Shs Outstand0.01B
Change-59.26%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Today10:12AMMoleculin Announces Pricing of $9.3 Million Public Offering(globenewswire.com)10:12AMMoleculin Announces Pricing of $9.3 Million Public Offering(globenewswire.com)08:10AMMoleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients(globenewswire.com)08:10AMMoleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients(globenewswire.com)
Jul 608:33AMMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment(globenewswire.com)08:33AMMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment(globenewswire.com)
Jun 3002:00PMWhy is Moleculin Stock Falling Today?(benzinga.com)08:30AMMoleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control(globenewswire.com)
Jun 408:31AMMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment(globenewswire.com)08:31AMMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment(globenewswire.com)
May 2908:21AMMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits(globenewswire.com)08:21AMMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits(globenewswire.com)
May 2105:02PMMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin(globenewswire.com)05:02PMMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin(globenewswire.com)
May 1508:30AMMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial(globenewswire.com)08:30AMMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial(globenewswire.com)
May 1312:41PMNano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding(benzinga.com)08:00AMMoleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks(globenewswire.com)
May 1209:30AMIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits(globenewswire.com)09:30AMIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits(globenewswire.com)
May 808:45AMMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin(globenewswire.com)08:45AMMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin(globenewswire.com)
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
KLEMP WALTER V
Option
28.8K
—
—
Nov 4, 25
KLEMP WALTER V
F
7.0K
$0.50
$4K
Nov 4, 25
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $185.00K | $68.00K | $18.00K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $-185.00K | $-68.00K | $-18.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $26.64M | $29.63M | $30.64M | $22.97M | $19.74M | $17.34M | $14.96M | $8.63M |
| Operating Income | $-26.64M | $-29.63M | $-30.64M | $-22.97M | $-19.74M | $-17.52M | $-15.03M | $-8.65M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-21.76M | $-29.77M | $-29.02M | $-15.89M | $-17.36M | $-13.21M | $-11.88M | $-9.80M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-158.00 | $-376.75 | $-380.50 | $-221.75 | $-661.00 | $-729.50 | $-1031.50 | $-1188.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Discover more
You may be interested in